CoChat

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy

Open access
Lamb, Rebecca, Fiorillo, Marco, Chadwick, Amy, Ozsvari, Bela, Reeves, Kimberly J., Smith, Duncan L., Clarke, Robert B., Howell, Sacha J., Cappello, Anna Rita, Martinez-Outschoorn, Ubaldo E., Peiris-Pagès, Maria, Sotgia, Federica, Lisanti, Michael P. · 2015 · Oncotarget
Cited by 114

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

// Rebecca Lamb 1, 2 , Marco Fiorillo 1, 2, 3 , Amy Chadwick 1, 2 , Bela Ozsvari 1, 2 , Kimberly J. Reeves 1, 2 , Duncan L. Smith 4 , Robert B. Clarke 1 , Sacha J. Howell 1 , Anna Rita Cappello 3 , Ubaldo E. Martinez-Outschoorn 5 , Maria Peiris-Pagès 1, 2 , Federica Sotgia 1, 2 , Michael P. Lisanti 1, 2 1 The Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK 2 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, UK 3 The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Italy 4 The Cancer Research UK Manchester Institute, University of Manchester, UK 5 The Sidney Kimmel Cancer Center, Philadelphia, PA, USA Correspondence to: Michael P. Lisanti, e-mail: michaelp.lisanti@gmail.com Federica Sotgia, e-mail: fsotgia@gmail.com Keywords: doxycycline, mitochondrial biogenesis, radiation resistance, proteomic analysis, DNA-PK Abbreviations: CSCs, cancer stem-like cells; TICs, tumor-initiating cells Received: February 21, 2015 Accepted: June 01, 2015 Published: June 13, 2015 ABSTRACT DNA-PK is an enzyme that is required for proper DNA-repair and is thought to confer radio-resistance in cancer cells. As a consequence, it is a high-profile validated target for new pharmaceutical development. However, no FDA-approved DNA-PK inhibitors have emerged, despite many years of drug discovery and lead optimization. This is largely because existing DNA-PK inhibitors suffer from poor pharmacokinetics. They are not well absorbed and/or are unstable, with a short plasma half-life. Here, we identified the first FDA-approved DNA-PK inhibitor by “chemical proteomics”. In an effort to understand how doxycycline targets cancer stem-like cells (CSCs), we serendipitously discovered that doxycycline reduces DNA-PK protein expression by nearly 15-fold (> 90%). In accordance with these observations, we show that doxycycline functionally radio-sensitizes breast CSCs, by up to 4.5-fold. Moreover, we demonstrate that DNA-PK is highly over-expressed in both MCF7- and T47D-derived mammospheres. Interestingly, genetic or pharmacological inhibition of DNA-PK in MCF7 cells is sufficient to functionally block mammosphere formation. Thus, it appears that active DNA-repair is required for the clonal expansion of CSCs. Mechanistically, doxycycline treatment dramatically reduced the oxidative mitochondrial capacity and the glycolytic activity of cancer cells, consistent with previous studies linking DNA-PK expression to the proper maintenance of mitochondrial DNA integrity and copy number. Using a luciferase-based assay, we observed that doxycycline treatment quantitatively reduces the anti-oxidant response (NRF1/2) and effectively blocks signaling along multiple independent pathways normally associated with stem cells, including STAT1/3, Sonic Hedgehog (Shh), Notch, WNT and TGF-beta signaling. In conclusion, we propose that the efficacy of doxycycline as a DNA-PK inhibitor should be tested in Phase-II clinical trials, in combination with radio-therapy. Doxycycline has excellent pharmacokinetics, with nearly 100% oral absorption and a long serum half-life (18–22 hours), at a standard dose of 200-mg per day. In further support of this idea, we show that doxycycline effectively inhibits the mammosphere-forming activity of primary breast cancer samples, derived from metastatic disease sites (pleural effusions or ascites fluid). Our results also have possible implications for the radio-therapy of brain tumors and/or brain metastases, as doxycycline is known to effectively cross the blood-brain barrier. Further studies will be needed to determine if other tetracycline family members also confer radio-sensitivity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4159

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Lamb, R., Fiorillo, M., Chadwick, A., Ozsvari, B., Reeves, K. J., Smith, D. L., Clarke, R. B., Howell, S. J., Cappello, A. R., Martinez-Outschoorn, U. E., Peiris-Pagès, M., Sotgia, F., & Lisanti, M. P.
Venue
Oncotarget
Published
2015-06-10
Volume
6
Issue
16
Pages
14005-14025
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1867175571
Cited by
114
References
3
FWCI
4.71
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.